Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetic Foot Ulcer01:31

Diabetic Foot Ulcer

Definition A diabetic foot ulcer (DFU) is a chronic, non-healing wound that develops in individuals with diabetes. It typically occurs on pressure-bearing areas such as the heel, metatarsal heads, or hallux, and carries a high risk of infection and amputation.Pathophysiology • The development of DFUs can be explained by four interconnected mechanisms: neuropathy, ischemia, infection, and impaired wound healing. • Neuropathy is the most common factor. Sensory neuropathy reduces pain perception,...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate,...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Peptic Ulcer01:27

Peptic Ulcer

Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the mucus...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Fear of Missing Out in Academic Workers: A Theoretical Framework.

Annals of the New York Academy of Sciences·2026
Same journal

The Importance of Studying the Cognitive Neuroscience of Aging Across Cultures.

Annals of the New York Academy of Sciences·2026
Same journal

Numbers Driving Space: Experience With Numerical Sequences Modulates Spatial Behavior in Newborn Chicks (Gallus gallus).

Annals of the New York Academy of Sciences·2026
Same journal

Escape From X-Chromosome Inactivation Enables Survival in a Male With an Unbalanced X;19 Translocation.

Annals of the New York Academy of Sciences·2026
Same journal

Singing Enhances Poetry Learning and Memorization in Preschool Children.

Annals of the New York Academy of Sciences·2026
Same journal

TMS-EEG Reveals Causal Dynamics of the Premotor Cortex during Musical Improvisation.

Annals of the New York Academy of Sciences·2026

Related Experiment Video

Updated: Jul 14, 2026

Mouse Model of Pressure Ulcers After Spinal Cord Injury
06:51

Mouse Model of Pressure Ulcers After Spinal Cord Injury

Published on: March 9, 2019

Pressure ulcers: a role for thymosin beta4.

Michael Francis Godschalk1

  • 1Virginia Commonwealth University School of Medicine, McGuire VA Medical Center, 1201 Broad Rock Blvd, Richmond, VA 23249, USA. Michael.Godschalk@VA.gov

Annals of the New York Academy of Sciences
|June 30, 2007
PubMed
Summary

Thymosin beta4 shows promise for accelerating pressure ulcer healing. This novel treatment demonstrated enhanced wound repair, including increased collagen and blood vessel formation in preclinical models.

More Related Videos

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
07:22

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

Related Experiment Videos

Last Updated: Jul 14, 2026

Mouse Model of Pressure Ulcers After Spinal Cord Injury
06:51

Mouse Model of Pressure Ulcers After Spinal Cord Injury

Published on: March 9, 2019

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
07:22

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

Area of Science:

  • Biomedical research
  • Wound healing science
  • Dermatology

Background:

  • Pressure ulcers affect up to 14% of hospitalized patients, causing significant pain and prolonged recovery.
  • Current treatments for pressure ulcers are lengthy, often taking months to achieve healing.
  • Effective treatments are needed to improve patient outcomes and reduce healthcare burdens.

Purpose of the Study:

  • To investigate the potential of thymosin beta4 as a novel therapeutic agent for pressure ulcers.
  • To evaluate the wound healing and anti-inflammatory properties of thymosin beta4.
  • To assess the impact of thymosin beta4 on key cellular processes involved in tissue repair.

Main Methods:

  • A preclinical study utilizing a rat full-thickness wound model.
  • Treatment administration of thymosin beta4 to assess its effects on wound healing.
  • Histological and molecular analyses to evaluate collagen deposition, angiogenesis, and reepithelialization.

Main Results:

  • Thymosin beta4 treatment significantly increased collagen deposition in the wound area.
  • Enhanced angiogenesis (new blood vessel formation) was observed in thymosin beta4 treated wounds.
  • Accelerated keratinocyte migration and reepithelialization were noted, indicating faster wound closure.

Conclusions:

  • Thymosin beta4 exhibits potent wound healing properties, including anti-inflammatory effects.
  • The compound promotes critical cellular mechanisms necessary for tissue regeneration.
  • Thymosin beta4 represents a promising therapeutic candidate for expediting pressure ulcer healing, potentially reducing treatment duration.